SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

M-M-R II

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 1971. No additional regulatory steps are needed for the current indication.
Why 3/10
No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for M-M-R II in the next 12 months. The vaccine has been approved and marketed for over 50 years. It is also a small component of Merck's $65B+ annual revenue, which is dominated by Keytruda, Gardasil, and other products. Per the rubric, an approved drug with no pending regulatory decision scores 3-5, and the low end is appropriate given the drug's maturity and modest contribution to Merck's overall value.
Actionable Insight NEUTRAL

M-M-R II has no scheduled binary catalysts. Merck investors should watch quarterly vaccine-segment revenue trends for signs of market-share erosion to GSK's Priorix, and monitor CDC/ACIP recommendation changes that could affect overall MMR vaccination rates. The more impactful near-term drivers for MRK stock are Keytruda patent-cliff dynamics, Gardasil sales trends, and pipeline readouts in oncology and cardiometabolic drugs.

Price Chart

Loading chart...

Executive Summary

M-M-R II is Merck's long-established combination vaccine against measles, mumps, and rubella (MMR), first FDA-approved in 1971 and continuously marketed for over 55 years. It remains the most-sold MMR vaccine in the US, but faces growing competition from GSK's interchangeable rival Priorix (approved in the US in 2022). For a Merck investor, M-M-R II is a mature, steady-revenue product within a massive, diversified pharmaceutical business. It has no upcoming binary catalysts and represents a very small portion of Merck's valuation, which is dominated by Keytruda, Gardasil, and the broader pipeline.

How It Works

M-M-R II is a combination vaccine containing live, weakened (attenuated) versions of the measles, mumps, and rubella viruses. When injected, it stimulates the immune system to produce antibodies against all three viruses without causing the diseases themselves, providing long-term protection.

Trial Status

M-M-R II was first FDA-approved on April 22, 1971, and has been continuously marketed for over 55 years. It is the most-sold MMR vaccine in the United States, based on IQVIA and CDC data from June 2022 through December 2024. The vaccine is recommended by the CDC's Advisory Committee on Immunization Practices (ACIP) as a two-dose series at 12-15 months and 4-6 years of age.

The Two-Sided Case

▲ Bull Case3
M-M-R II is the most-sold MMR vaccine in the US, with over 231 million doses distributed over three decades, giving it entrenched market position and physician familiarity.
Rising measles outbreaks due to declining vaccination rates and vaccine hesitancy could drive increased demand for MMR vaccination, benefiting M-M-R II.
The global MMR vaccines market is projected to grow at a CAGR of 5.5-12.6% through the early 2030s, providing steady tailwinds for an established product.
▼ Bear Case3
GSK's Priorix, FDA-approved in June 2022 and licensed in over 100 countries, is a direct competitor that the CDC considers fully interchangeable with M-M-R II, creating pricing and market-share pressure.
As a mature vaccine first approved in 1971, M-M-R II faces no patent protection and is a small, undifferentiated part of Merck's massive $65B+ portfolio, limiting its ability to move Merck's stock.
Potential policy changes, such as executive orders altering childhood vaccine recommendations, could reduce overall MMR vaccination rates and demand.

Upcoming Catalysts

  • None scheduled. M-M-R II is a mature, approved vaccine with no pending FDA decision, pivotal readout, or label-expansion catalyst in the next 12 months.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 9

Hover a chip for the title
1 merckvaccines.com2 fda.gov3 purplebooksearch.fda.gov4 merck.com5 cnbc.com6 biospace.com7 merck.com8 fortunebusinessinsights.com9 sec.gov